Skip to content

A Clinical trial to study the efficacy of Hruswapanchamula Taila as Nasya and Uttarabhaktika Snehapana in subjects of Avabahuka vis-a-vis Frozen Shoulder

A Comparative Clinical Study to Evaluate the Efficacy of Nasya and Uttarabhaktika Snehapana with Hruswapanchamula Taila in the Management of Avabahuka vis-a-vis Frozen Shoulder - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/065182
Enrollment
40
Registered
2024-04-04
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M750- Adhesive capsulitis of shoulder

Interventions

None listed

Sponsors

Dr Spoorthi UB
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects fulfilling the Diagnostic criteria. 2. Subjects between the age group of 25-60 years, irrespective of gender. 3. Subjects fit for Snehapana and Nasya Karma.

Exclusion criteria

Exclusion criteria: 1. Subjects with the history of fracture and dislocation of shoulder joint. 2. Subjects suffering from any other systemic disorders which interferes with the course of intervention. 3. Subjects having HbA1c more than 7.65 4. Pregnant women and lactating mothers.

Design outcomes

Primary

MeasureTime frame
Efficacy of Nasya with Hruswapanchamoola taila in reducing pain as well as stiffness and improvement in the Range of Movement.Timepoint: 8th day

Secondary

MeasureTime frame
Efficacy of Nasya & Uttarabhaktika Snehapana with Hruswapanchamoola taila in improving the range of motion of the affected shoulder joints by comparing the readings of Goniometer before & after the intervention.Timepoint: 8thday 15thday

Countries

India

Contacts

Public ContactDr Spoorthi UB

Government Ayurveda Medical College, Mysuru

kulkarnidrvarsha@gmail.com7676848402

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026